The FDA granted orphan drug designation to APX005M for the treatment of three gastrointestinal cancer types, according to the agent’s manufacturer.
FDA grants orphan drug designation to APX005M for three cancer types
The FDA granted orphan drug designation to APX005M for the treatment of three gastrointestinal cancer types, according to the agent’s manufacturer.